Interview with the CEO of Prostatype Genomics

By Modular Finance

Nyemissioner.se has conducted an interview with Fredrik Rickman, CEO of Prostatype Genomics. In the article, published on the Nyemissioner.se news page, Fredrik Rickman discusses new long-term data demonstrating significant added value for the company’s genetic test, Prostatype®, compared to the NCCN’s established risk classification system. He also addresses the status of the company’s ongoing process with Medicare regarding reimbursement in the US; a working meeting with Medicare is scheduled for early November.

The company will update the market when further relevant information regarding the process becomes available.

The full article (in Swedish) can be read at the following link:

https://nyemissioner.se/nyheter/prostatype-visar-starka-langtidsdata-medicare-processen-gar-vidare/

For more information about the Company, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

E-mail: fredrik.rickman@prostatypegenomics.com

Certified Adviser

Tapper Partners AB

Telephone: +46 (0)70 44 010 98

E-mail: ca@tapperpartners.se

About Prostatype Genomics

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Attachments
Interview with the CEO of Prostatype Genomics

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.